506 related articles for article (PubMed ID: 29400127)
1. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
Balestrino R; Schapira AHV
Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase Mutations in Parkinson Disease.
O'Regan G; deSouza RM; Balestrino R; Schapira AH
J Parkinsons Dis; 2017; 7(3):411-422. PubMed ID: 28598856
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
4. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
5. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
6. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
[TBL] [Abstract][Full Text] [Related]
7. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
Vieira SRL; Schapira AHV
Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
Beavan MS; Schapira AH
Ann Med; 2013 Dec; 45(8):511-21. PubMed ID: 24219755
[TBL] [Abstract][Full Text] [Related]
9. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
[TBL] [Abstract][Full Text] [Related]
10. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.
Galvagnion C; Marlet FR; Cerri S; Schapira AHV; Blandini F; Di Monte DA
Brain; 2022 Apr; 145(3):1038-1051. PubMed ID: 35362022
[TBL] [Abstract][Full Text] [Related]
11.
Smith L; Schapira AHV
Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
[TBL] [Abstract][Full Text] [Related]
12. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
13. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M; Anderson DG; Grobler AF
Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase and parkinsonism: lessons to learn.
Marković I; Kresojević N; Kostić VS
J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
Gegg ME; Menozzi E; Schapira AHV
Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
[TBL] [Abstract][Full Text] [Related]
17. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
18. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
Li H; Ham A; Ma TC; Kuo SH; Kanter E; Kim D; Ko HS; Quan Y; Sardi SP; Li A; Arancio O; Kang UJ; Sulzer D; Tang G
Autophagy; 2019 Jan; 15(1):113-130. PubMed ID: 30160596
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
